Zhao Jia-Lin, Zhang Zheng-Hao, Wang Rui, Yuan Hai-Long, Chen Gang, Zhang Juan, Muhashi Ma-Li-Ya, Qu Jian-Hua
Center of Blood Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China.
Center of Blood Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China.E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Feb;27(1):20-24. doi: 10.7534/j.issn.1009-2137.2019.01.004.
To study the expression of SOX4 gene in patients with acute myeloid leukemia (AML) and its correlation with clinical features and prognosis, and to explore the role of this gene in acute myeloid leukemia.
The real-time guantitative PCR was used to detect the expression level of SOX4 gene in bone marrow of 96 patients with newby diagmsed AML, and the features and prognosis was analyzed.
The level of SOX4 expression in the 96 AML patients was significantly higher than that in healthy controls (P<0.01), and the expression of SOX4 gene was not significanly different between M1-M5 (P<0.05). The expression of SOX4 gene was no significanly different between different sex, nationality, and remission after chemotherapy (P>0.05). In AML patients the SOX4 gene expression level did not significantly correlated with the white blood cell count, hemoglobin level, platelet count primitive cell count, reticulocyte count and other laboratory indexes ( P>0.05), while which correlated with the overall survival (OS) (P<0.01) and erent-free survival (EFS) (P<0.05).
The high expression of SOX4 gene affects the survival time of patients (OS, EFS), suggesting that may be one of the unfavorable prognostic factors for the AML patients.
研究急性髓系白血病（AML）患者中SOX4基因的表达情况及其与临床特征和预后的相关性，探讨该基因在急性髓系白血病中的作用。
采用实时定量PCR检测96例初诊AML患者骨髓中SOX4基因的表达水平，并分析其特征及预后。
96例AML患者的SOX4表达水平显著高于健康对照（P<0.01），M1-M5各型之间SOX4基因表达无显著差异（P>0.05）。不同性别、民族及化疗后缓解情况患者的SOX4基因表达无显著差异（P>0.05）。AML患者中SOX4基因表达水平与白细胞计数、血红蛋白水平、血小板计数、原始细胞计数、网织红细胞计数等实验室指标无显著相关性（P>0.05），而与总生存期（OS）相关（P<0.01），与无事件生存期（EFS）相关（P<0.05）。
SOX4基因的高表达影响患者生存时间（OS、EFS），提示其可能是AML患者不良预后因素之一。
